Skip to main content

February 2012 - FRMC

02/22/2012
Although vemurafenib improves outcomes in patients with advanced melanoma that harbors a BRAF gene mutation, the drug also accelerates the development of squamous-cell carcinomas and keratoacanthomas in some patients. Results that show a skin...
Although vemurafenib improves outcomes in patients with advanced melanoma that harbors a BRAF gene mutation, the drug also accelerates the development of squamous-cell carcinomas and keratoacanthomas in some patients. Results that show a skin...
Although vemurafenib improves...
02/22/2012
First Report Managed Care
02/22/2012
Human papillomavirus (HPV) is the most prevalent sexually transmitted infection (STI) in the United States. HPV has a prevalence of 29.5% in sexually experienced girls 14 to 19 years of age. Sequelae of HPV infection may include genital...
Human papillomavirus (HPV) is the most prevalent sexually transmitted infection (STI) in the United States. HPV has a prevalence of 29.5% in sexually experienced girls 14 to 19 years of age. Sequelae of HPV infection may include genital...
Human papillomavirus (HPV) is...
02/22/2012
First Report Managed Care
02/22/2012
New Orleans—According to an analysis of clinical trials, bazedoxifene is effective as a second-line therapy for postmenopausal women who have osteoporosis, although the drug is not cost-effective compared with raloxifene. Bazedoxifene and...
New Orleans—According to an analysis of clinical trials, bazedoxifene is effective as a second-line therapy for postmenopausal women who have osteoporosis, although the drug is not cost-effective compared with raloxifene. Bazedoxifene and...
New Orleans—According to an...
02/22/2012
First Report Managed Care
02/22/2012
A study comparing the cost of fulvestrant found that 250 mg appears to be a cost-effective option in treating postmenopausal women with breast cancer.
A study comparing the cost of fulvestrant found that 250 mg appears to be a cost-effective option in treating postmenopausal women with breast cancer.
A study comparing the cost of...
02/22/2012
First Report Managed Care
02/22/2012
New Orleans—A retrospective cohort study found that patients with atrial fibrillation (AF) who took dabigatran did not have a significant reduction in length of stay in a hospital compared with those who took warfarin. However, the authors...
New Orleans—A retrospective cohort study found that patients with atrial fibrillation (AF) who took dabigatran did not have a significant reduction in length of stay in a hospital compared with those who took warfarin. However, the authors...
New Orleans—A retrospective...
02/22/2012
First Report Managed Care
02/22/2012
To determine survival benefits for patients with hormone-refractory prostate cancer, researchers looked at treating HRPC with sipuleucel-T and docetaxel.
To determine survival benefits for patients with hormone-refractory prostate cancer, researchers looked at treating HRPC with sipuleucel-T and docetaxel.
To determine survival benefits...
02/22/2012
First Report Managed Care
02/22/2012
Chicago—Data from a large epidemiologic study presented at the ACR meeting suggest a trend toward reduced cardiovascular disease (CVD) risk among patients with rheumatoid arthritis (RA) during the first 6 months of initiating treatment with...
Chicago—Data from a large epidemiologic study presented at the ACR meeting suggest a trend toward reduced cardiovascular disease (CVD) risk among patients with rheumatoid arthritis (RA) during the first 6 months of initiating treatment with...
Chicago—Data from a large...
02/22/2012
First Report Managed Care

Department

News Connection
02/22/2012
A vaccine for genital herpes was effective in protecting some women from genital disease and infection from herpes simplex type 1 but not from type 2.
A vaccine for genital herpes was effective in protecting some women from genital disease and infection from herpes simplex type 1 but not from type 2.
A vaccine for genital herpes was...
02/22/2012
First Report Managed Care
Conference Insider
02/22/2012
Chicago—The risk of serious infection was not significantly increased in patients with autoimmune diseases initiating treatment with tumor necrosis factor (TNF) antagonists compared with those treated with nonbiologic disease regimens, even...
Chicago—The risk of serious infection was not significantly increased in patients with autoimmune diseases initiating treatment with tumor necrosis factor (TNF) antagonists compared with those treated with nonbiologic disease regimens, even...
Chicago—The risk of serious...
02/22/2012
First Report Managed Care
Conference Insider
02/22/2012
Chicago—Patients treated with anti–tumor necrosis factor (TNF) therapy for rheumatoid arthritis (RA) are not at increased risk of solid cancers compared with patients receiving nonbiologic disease-modifying antirheumatic drugs (DMARDs),...
Chicago—Patients treated with anti–tumor necrosis factor (TNF) therapy for rheumatoid arthritis (RA) are not at increased risk of solid cancers compared with patients receiving nonbiologic disease-modifying antirheumatic drugs (DMARDs),...
Chicago—Patients treated with...
02/22/2012
First Report Managed Care